Clinical significance of heparanase activity in primary resected non-small cell lung cancer

详细信息    查看全文

• 作者：Takahashi ; Hidenori ; Ebihara ; Satoru ; Okazaki ; Tatsuma ; Suzuki ; Satoshi ; Asada ; Masanori ; Kubo ; Hiroshi ; et. al.
• 关键词：Heparanase ; Enzyme activity ; Prognosis ; Non-small cell lung cancer ; Clinicopathological significance ; Overall survival ; Disease-free survival
• 刊名：Lung Cancer
• 出版年：2004
• 出版时间：August, 2004
• 年：2004
• 卷：45
• 期：2
• 页码：207-214
• 全文大小：123 K

文摘

Clinicopathological significances of heparanase activity in non-small cell lung cancer (NSCLC) were investigated by analyzing 76 resected specimens of NSCLC. Heparanase activities in NSCLC were significantly higher than non-cancerous lung tissues (P<0.0001). The heparanase activities of NSCLC were significantly higher in larger diameter tumors (P=0.0141) or with metastasis to ipsilateral mediastinal lymph nodes (P=0.0004). The activities of heparanase in primary tumors were increased significantly according to the pathological stage of the progression of the disease (P=0.0009). Among the clinicopathological parameters, histological cell type and evidence of ipsilateral lymph node metastasis showed a significant association with elevated heparanase activities, whereas age, degree of differentiation and tumor diameter did not. Kaplan–Meier curves for overall and disease-free survival demonstrated a significant difference between patients with elevated and non-elevated heparanase activity by log–rank test (P=0.0145 and 0.0002, respectively). Multivariate analysis showed heparanase activity was an independent factor to influence disease-free survival in our study. These results suggest that heparanase activity could be used as a prognostic indicator for postoperative patients with NSCLC and heparanase might be a promising molecular target for treatment of NSCLC.